Weekly Recap | SBP GROUP -7.35%, consensus target above spot

LongbridgeAII'm LongbridgeAI, I can summarize articles.

The Week

SBP GROUP (1177.HK) fell 7.35% this week to close at HK$5.105, while the Hang Seng Index lost 5.65%, leaving the stock about 1.7 percentage points behind the benchmark. It opened Monday at HK$5.5, held a narrow range through Tuesday and Wednesday, then dropped on Thursday to a weekly low of HK$5.075 before settling at HK$5.105. The weekly amplitude was 8.18%. The close sits below the 20-day average of HK$5.243 and the 60-day average of HK$5.404, in the lower half of the past 60-session range.

Key Events

The week centred on the 2026 national medical insurance catalogue update. On Monday China announced a record 51 innovative drugs had been added to the public insurance list. On Wednesday CMBI raised its target price for SBP GROUP to HK$9, citing several innovative drugs included in the scheme. On Thursday Citi noted the negotiation results showed only mild and manageable price cuts. Yet on Friday the stock was down more than 5% intraday and ended the week lower.

Analyst Ratings

Among 23 institutions covering the name, 21 rate it buy or overweight—16 buy and 5 overweight—while 2 rate it hold; there are no underweight or sell ratings. The consensus recommendation is strong buy, with a consensus target price of HK$8.505, roughly 66.6% above the spot price of HK$5.105. Target price estimates range from HK$5.96 to HK$11.017, a wide spread. Within the pharmaceutical sector, the stock ranks second among 29 names by analyst coverage count.

The Week Ahead

SBP GROUP is scheduled to report its fiscal 2026 third-quarter results after the close on Monday, 30 November 2026. Full-year 2026 results are expected on 25 March 2027. The near-term focus is on the pace of innovative drug sales after the insurance listing, and on management guidance regarding the magnitude of price reductions.

In Short

The week brought confirmation that 51 innovative drugs entered the national medical insurance catalogue, including several from SBP GROUP, yet the stock still dropped 7.35% and lagged the market. The analyst backdrop is supportive, with wide coverage and a consensus target well above spot, but the latest trading day shows small-lot flows turning more negative than large-lot flows, suggesting weak near-term support. The key test is the 30 November earnings update, where management commentary on innovative drug revenue volume and margins will help show whether the insurance additions can translate into estimate revisions.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.

Source: Weekly Review The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.